Literature DB >> 8006374

New insights into the pathogenesis of congenital myopathies.

H B Sarnat1.   

Abstract

Congenital myopathies are developmental disorders of muscle that are best understood in the context of ontogenesis. Segmental amyoplasia results from a defective somite, usually because of lack of induction by the notochord and neural tube; the connective tissue matrix of the muscle is derived from lateral mesoderm and is present, but the myocytes are derived from somitic mesoderm and are replaced by adipose cells. Generalized amyoplasia is due to defective myogenic regulatory genes. X-linked recessive myotubular myopathy is associated with overexpression of vimentin and desmin, fetal intermediate filaments that attach to nuclear, mitochondrial, and inner sarcolemmal membranes and Z-bands of sarcomeres to preserve the morphologic organization of the myotube. Neonatal myotonic dystrophy is a true maturational delay in muscle development. Congenital muscle fiber-type disproportion is a syndrome of multiple etiologies but in some cases is associated with cerebellar hypoplasia and may be the result of abnormal suprasegmental stimulation of the developing motor unit at 20 to 28 weeks' gestation, mediated through bulbospinal pathways but not the corticospinal tract. Maturational delay of muscle in late developmental stages is less specific than in stages before midgestation. The Proteus syndrome is a muscular dysgenesis; abnormal paracrine growth factors and perhaps altered genes that regulate muscle differentiation and growth, such as myoD and myogenin, are the suspected cause. Focal proliferative myositis may be another example of a "paracrine myopathy."

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006374     DOI: 10.1177/088307389400900218

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya.

Authors:  H Ohto; S Kamada; K Tago; S I Tominaga; H Ozaki; S Sato; K Kawakami
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Beyond the "Jewish panel": the importance of offering expanded carrier screening to the Ashkenazi Jewish population.

Authors:  Shelley Dolitsky; Anjali Mitra; Shama Khan; Elena Ashkinadze; Mark V Sauer
Journal:  F S Rep       Date:  2020-08-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.